Valeant, Eli Lilly, J&J, Regeneron and GSK
– After Valeant Pharmaceuticals acquires the Bausch + Lomb global ophthalmology business for $8.7 billion, Healio reports Bausch + Lomb to Operate as Independent Unit After Acquisition. The deal is expected to be completed in the third quarter after standard regulatory approvals and Valeant has reassured Bausch + Lomb employees that there will be no cutting of the sales force in North America
– Mobile apps are nothing new for Lilly Oncology. Eli Lilly Backs Mobile App for Cancer Docs from FierceBiotechIT introduces the latest app, called MDLinx, available for iPhone and Android devices. The app provides reviews of journal articles, aiming to help keep busy physicians abreast of the latest research in their areas of specialty or interest. The idea is to provide the free app for oncologists across a variety of specialty areas to corral relevant information from the dozens of journal articles published every day
– With a unique model of innovation, the Pharmaceuticals segment of Johnson & Johnson has built an industry-leading pipeline that has yielded 11 new product launches since 2009, more than doubling its productivity over the past four years. Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017 details the recent announcement that they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017
– Regeneron is now the largest biotech player focused almost exclusivity in the field of antibody companies. With three-monthly sales of $314 million, management reiterated that full-year revenues for 2013 are expected to hit $1.3 billion. Forbes covers this news in The Logic Of Biologics – Is Regeneron The Next Genentech?
– Last month, Ashoka Changemakers announced four winners of its ‘League of Intrapreneurs: Building Better Business from the Inside Out’ competition, honoring initiatives within organizations that are pioneering game-changing models for business and society. GlaxoSmithKline (GSK) was chosen for its work in developing simple, cheap, paper-based devices capable of diagnosing infections and saving millions of lives. Sustainable Brands’ GSK Building Better Business from the Inside Out by Bringing Low-Cost Diagnostics to Africa discusses the breakthrough project with Graham Simpson, principal scientist at GSK
